Ken Frazier, AP Images
June 2, 2020 11:17 AM EDTUpdated July 15, 06:59 AM
People
R&D
In Focus

Why Mer­ck wait­ed, and what they now bring to the Covid-19 fight

Jason Mast

Editor

Nicholas Kart­so­nis had been run­ning clin­i­cal in­fec­tious dis­ease re­search at Mer­ck for al­most 2 years when, in mid-Jan­u­ary, he got a new as­sign­ment: search­ing the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

A service from the Financial Times